Press release archive - GSK
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category. Press releases issued by our local operating companies …
GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep …
3 days ago · On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase 3 trial of Blenrep (belantamab …
Blenrep shows overall survival benefit in head-to-head DREAMM-7 ... - GSK
4 days ago · Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The overall survival results from the DREAMM-7 trial underscore the potential for this Blenrep …
GSK reports positive outcomes from Phase III multiple myeloma …
3 days ago · GSK has announced positive headline interim analysis outcomes from a Phase III trial, which is evaluating Blenrep (belantamab mafodotin) along with bortezomib and …
GSK’s Withdrawn Blood Cancer Drug Reduced Risk of Death in Trial
4 days ago · GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, further boosting the prospects of bringing the …
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2
Oct 9, 2024 · GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company …
GSK hails progress for withdrawn blood cancer drug - Financial …
4 days ago · GSK hailed progress for its withdrawn blood cancer drug Blenrep on Thursday, raising the prospect of the treatment returning to market after the drugmaker announced …
GSK invests up to $800 million in Pennsylvania site, largest ...
Oct 24, 2024 · The up to $800 million investment will bring state-of-the-art drug substance manufacturing and additional drug product manufacturing capabilities to the company’s site in …
GSK makes a strong start to 2024 with improving outlook for the …
May 1, 2024 · Now expect 2024 turnover growth towards the upper part of 5% to 7% range; Core operating profit growth of 9% to 11% (previously 7% to 10%); Core EPS growth of 8% to 10% …
Press releases | GSK US
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology …